124 related articles for article (PubMed ID: 23585158)
1. Multiplicity considerations for subgroup analysis subject to consistency constraint.
Alosh M; Huque MF
Biom J; 2013 May; 55(3):444-62. PubMed ID: 23585158
[TBL] [Abstract][Full Text] [Related]
2. A flexible strategy for testing subgroups and overall population.
Alosh M; Huque MF
Stat Med; 2009 Jan; 28(1):3-23. PubMed ID: 18985704
[TBL] [Abstract][Full Text] [Related]
3. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
Wang SJ; Hung HM; O'Neill R
J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
[TBL] [Abstract][Full Text] [Related]
4. Interaction effects and subgroup analyses in clinical trials: more than meets the eye?
Sevdalis N; Jacklin R
J Eval Clin Pract; 2008 Oct; 14(5):919-22. PubMed ID: 18373582
[TBL] [Abstract][Full Text] [Related]
5. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
[TBL] [Abstract][Full Text] [Related]
6. An overview of statistical and regulatory issues in the planning, analysis, and interpretation of subgroup analyses in confirmatory clinical trials.
Hemmings R
J Biopharm Stat; 2014; 24(1):4-18. PubMed ID: 24392975
[TBL] [Abstract][Full Text] [Related]
7. Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials.
Alosh M; Huque MF; Bretz F; D'Agostino RB
Stat Med; 2017 Apr; 36(8):1334-1360. PubMed ID: 27891631
[TBL] [Abstract][Full Text] [Related]
8. Multiplicity considerations in subgroup analysis.
Dmitrienko A; Millen B; Lipkovich I
Stat Med; 2017 Dec; 36(28):4446-4454. PubMed ID: 28762525
[TBL] [Abstract][Full Text] [Related]
9. Subgroups: time to go back to basic statistical principles?
Keene ON; Garrett AD
J Biopharm Stat; 2014; 24(1):58-71. PubMed ID: 24392978
[TBL] [Abstract][Full Text] [Related]
10. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
11. A consistency-adjusted alpha-adaptive strategy for sequential testing.
Alosh M; Huque MF
Stat Med; 2010 Jul; 29(15):1559-71. PubMed ID: 20552571
[TBL] [Abstract][Full Text] [Related]
12. Clinical trials of behavioural interventions with heterogeneous teaching subgroup effects.
Hoover DR
Stat Med; 2002 May; 21(10):1351-64. PubMed ID: 12185889
[TBL] [Abstract][Full Text] [Related]
13. Gatekeeping procedures with clinical trial applications.
Dmitrienko A; Tamhane AC
Pharm Stat; 2007; 6(3):171-80. PubMed ID: 17583553
[TBL] [Abstract][Full Text] [Related]
14. General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials.
Dmitrienko A; Muysers C; Fritsch A; Lipkovich I
J Biopharm Stat; 2016; 26(1):71-98. PubMed ID: 26366479
[TBL] [Abstract][Full Text] [Related]
15. Addressing multiplicity issues of a composite endpoint and its components in clinical trials.
Huque MF; Alosh M; Bhore R
J Biopharm Stat; 2011 Jul; 21(4):610-34. PubMed ID: 21516560
[TBL] [Abstract][Full Text] [Related]
16. Rationale for a non-inferiority clinical trial design focused on subpopulations.
Kulkarni PM; Meadows ES; Ahuja S; Muram D; Plouffe L
Curr Med Res Opin; 2004 Oct; 20(10):1641-7. PubMed ID: 15462697
[TBL] [Abstract][Full Text] [Related]
17. Interpretation of subgroup effects in published trials.
Hancock MJ; Kjaer P; Korsholm L; Kent P
Phys Ther; 2013 Jun; 93(6):852-9. PubMed ID: 23431217
[TBL] [Abstract][Full Text] [Related]
18. The role of the minimum clinically important difference and its impact on designing a trial.
Chuang-Stein C; Kirby S; Hirsch I; Atkinson G
Pharm Stat; 2011; 10(3):250-6. PubMed ID: 20936625
[TBL] [Abstract][Full Text] [Related]
19. Evidence of subgroup-specific treatment effect in the absence of an overall effect: is there really a contradiction?
Abrahamowicz M; Beauchamp ME; Fournier P; Dumont A
Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1178-88. PubMed ID: 23939947
[TBL] [Abstract][Full Text] [Related]
20. Adjusted significance levels for subgroup analyses in clinical trials.
Spiessens B; Debois M
Contemp Clin Trials; 2010 Nov; 31(6):647-56. PubMed ID: 20832503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
